Current Research Studies

FIERCe: FOLR1 Immune Effector Cell Therapy against Advanced Osteosarcoma

FIERCe

Phase: I
Clinicaltrials.gov ID: NCT07227571

What is the goal of the study?

The study will be a Phase 1, open-label, nonrandomized interventional study aimed at treating up to 30 individuals with advanced osteosarcoma. All participants are intended to receive study interventions. FH-FOLR1 ST CAR T cell therapy is the investigational product under evaluation

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Michelle Choe
Study Team Member: Immunotherapy CRAs, [email protected]